Dermata Therapeutics (DRMA)
(Delayed Data from NSDQ)
$2.23 USD
0.00 (0.00%)
Updated Jul 3, 2024 12:59 PM ET
After-Market: $2.27 +0.04 (1.79%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.23 USD
0.00 (0.00%)
Updated Jul 3, 2024 12:59 PM ET
After-Market: $2.27 +0.04 (1.79%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug
by Zacks Equity Research
Dermata (DRMA) announces reaching an agreement with the FDA to begin a late-stage pivotal clinical program for its acne treatment candidate, DMT310. The stock rises 7%.
Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate
by Zacks Equity Research
Dermata (DRMA) gains on positive FDA response for the further development of DMT310 for treating severe to moderate acne.